WEREWOLF THERAPEUTICS, INC. Deferred Revenue Recognized
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Deferred Revenue Recognized of $5.00 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2023-11-14
- WEREWOLF THERAPEUTICS, INC. contract with customer, liability, revenue recognized for the quarter ending 2023-09-30 was $5.00M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 9 month |
|---|---|---|
| 2023-09-30 | $5.00M 10-Q · filed 2023-11-14 | $5.00M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |